Improved Survival After Percutaneous Coronary Intervention of Chronic Total Occlusion Varies by Target Vessel
Safley et al. (1) conducted an important multivariable analysis to determine predictors of success in treating chronic total occlusion and clinical outcomes. As part of their conclusions, they stated that the use of glycoprotein IIb/IIIa was significantly associated with improved success (odds ratio: 2.27, 95% confidence interval: 1.36 to 4.80). However, we feel that the inclusion of glycoprotein IIb/IIIa in models to predict success and outcome is inappropriate, (6), and Medina (7). Reproduced with permission from Colombo et al. (8) . Double box indicates a true bifurcation lesion. Medina (7) class: 1. main branch proximal lesion Ͼ50% ϭ 1, Ͻ50% ϭ 0; 2. main branch distal lesion Ͼ50% ϭ 1, Ͻ50% ϭ 0; 3. side branch lesion Ͼ50% ϭ 1, Ͻ50% ϭ 0.
as glycoprotein IIb/IIIa is typically used after and not before the chronic total occlusion has been crossed with a guidewire with reasonable assurance that the wire is intraluminal distally. Therefore, we question whether glycoprotein IIb/IIIa use has any impact on chronic total occlusion success rates. Further, its inclusion in the models can potentially impact the point estimates of other important variables. More importantly, the use of glycoprotein IIb/IIIa before successful crossing of a chronic total occlusion may increase the risk of pericardial effusion or tamponade. It would be of interest to conduct the same analysis without the inclusion of glycoprotein IIb/IIIa to observe whether other important variables are predictive of success and outcome in this cohort.
Reply
Drs. Shishehbor and Whitlow raise an excellent point regarding our analysis of predictors of procedural success in chronic total occlusion (CTO) angioplasty (1). There are several aspects regarding the use of glycoprotein (GP) IIb/IIIa antagonist use in CTO percutaneous coronary intervention (PCI) that need to be recognized to put the results of our analysis in context. First, GP IIb/IIIa antagonists were used in the later years of our analysis. Second, GP IIb/IIIa antagonists were administered after successful crossing of the target lesion in CTO PCI in the vast majority of cases. Third, GP IIb/IIIa is not a patient pre-procedural variable and thus is subject to important selection bias. We think including GP IIb/IIIa antagonist use in our model is justified to evaluate the possibility of both benefit and harm. In our analysis there did not seem to be any signal for harm. However, their use in the manner described above does bias this analysis. We have described technical success (crossing the lesion and performing angioplasty with or without stenting and Ͻ40% residual stenosis) as well as procedural success (technical success without major adverse clinical events while in the hospital). Therefore, using GP IIb/IIIa antagonists only in patients who have already had a successful crossing of their CTO lesion does increase the likelihood that they will have procedural success by the virtue of being well on the way to technical success. We agree wholeheartedly that these agents should be administered only after the lesion has been crossed and intraluminal wire position has been confirmed. We have repeated the analysis excluding GP IIb/IIIa antagonist use from the model, and the point estimates for the other variables are not significantly altered. In conclusion, we thank Drs. Shishehbor and Whitlow for raising this important point regarding the use of GP IIb/IIIa antagonists in CTO angioplasty and allowing us to expand on this important element of CTO PCI.
